Cytek Biosciences, Inc. (CTKB) stock
CTKBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/300% below fair value
$6.12−0.20 (-3.16%)
Close on Nov 20, 2026Market cap $795.50MP/E –Yield –
Cytek Biosciences free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Cytek Biosciences's free cash flow for the twelve months ending Jun 30, 2026 was -$12.08M, down 211.1% year over year. For fiscal 2025 it was -$8.77M, down 140.1% from the year before. The highest annual figure on record is $21.85M in fiscal 2024.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$8.77M | -140.1% |
| FY2024 | Dec 31, 2024 | $21.85M | +3352.4% |
| FY2023 | Dec 31, 2023 | $633.00K | – |
| FY2022 | Dec 31, 2022 | -$21.98M | -8362.8% |
| FY2021 | Dec 31, 2021 | $266.00K | -98.0% |
| FY2020 | Dec 31, 2020 | $13.61M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$849.00K | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.90M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.77M | -260.7% |
| Q3 FY2025 | Sep 30, 2025 | -$4.56M | -137.3% |
| Q2 FY2025 | Jun 30, 2025 | -$1.47M | -128.5% |
| Q1 FY2025 | Mar 31, 2025 | -$974.00K | -128.7% |
| Q4 FY2024 | Dec 31, 2024 | $1.10M | -86.2% |
| Q3 FY2024 | Sep 30, 2024 | $12.21M | – |
| Q2 FY2024 | Jun 30, 2024 | $5.15M | – |
| Q1 FY2024 | Mar 31, 2024 | $3.39M | +44.1% |
| Q4 FY2023 | Dec 31, 2023 | $8.01M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.57M | – |
| Q2 FY2023 | Jun 30, 2023 | -$4.16M | – |
| Q1 FY2023 | Mar 31, 2023 | $2.35M | – |
| Q4 FY2022 | Dec 31, 2022 | -$337.00K | -108.1% |
| Q3 FY2022 | Sep 30, 2022 | -$8.61M | – |
| Q2 FY2022 | Jun 30, 2022 | -$10.77M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.26M | -258.5% |
| Q4 FY2021 | Dec 31, 2021 | $4.15M | -63.7% |
| Q3 FY2021 | Sep 30, 2021 | -$147.00K | -108.6% |
| Q2 FY2021 | Jun 30, 2021 | -$5.17M | – |
| Q1 FY2021 | Mar 31, 2021 | $1.43M | – |
| Q4 FY2020 | Dec 31, 2020 | $11.44M | – |
| Q3 FY2020 | Sep 30, 2020 | $1.72M | – |
See a number that looks wrong?